Loading stock data…
CytomX Therapeutics, Inc. (CTMX)
$3.65-0.06 (-1.62%)
Market ClosedLast close Sep 8
CytomX Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CytomX Therapeutics, Inc. in the Healthcare sector is trading at $3.65 with a market capitalization of $732M. Wall Street consensus targets $12.25 (8 analysts), implying a +235.6% move over the next 12 months. The stock is currently 56% below its 52-week high of $8.21, remaining 12.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +235.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.42M↓ | $10.26M↑ | $663,000↓ | $5.96M↓ | $18.66M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$23.78M↓ | -$19.67M↑ | -$27.93M↓ | -$15.77M↓ | -$1.29M |
| Net Income | -$20.67M↓ | -$18.25M↑ | -$26.51M↓ | -$14.23M↓ | -$154,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology bio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$732.14M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.37%
Volume
Today's trading volume
1.98M
Recent News
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...
Strong clinical progress and expanded Regeneron collaboration bolster CytomX's path forward despite revenue decline and safety considerations.
CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now?
CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its research collaboration with Regeneron to develop next-gen conditionally-activated bispecific cancer therapies. By combining CytomX’s PROBODY masking platform with Regeneron’s Veloci-Bi technology, the partnership aims to create treatments that remain inactive until reaching the […]